CIBC Private Wealth Group LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 35.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,416,810 shares of the company’s stock after purchasing an additional 1,693,064 shares during the period. CIBC Private Wealth Group LLC owned 0.24% of AstraZeneca worth $319,044,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. Arkadios Wealth Advisors acquired a new position in AstraZeneca in the 4th quarter valued at about $28,000. Concord Wealth Partners acquired a new position in AstraZeneca in the 4th quarter valued at about $34,000. IronBridge Private Wealth LLC acquired a new position in AstraZeneca in the 4th quarter valued at about $35,000. Jackson Grant Investment Advisers Inc. acquired a new position in AstraZeneca in the 4th quarter valued at about $38,000. Finally, SOA Wealth Advisors LLC. acquired a new position in shares of AstraZeneca during the 4th quarter worth approximately $38,000. Institutional investors own 16.13% of the company’s stock.
Shares of AZN traded up $0.05 during trading hours on Friday, hitting $58.89. 199,969 shares of the stock were exchanged, compared to its average volume of 9,962,940. The company has a quick ratio of 0.67, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $154.56 billion, a price-to-earnings ratio of 38.70, a P/E/G ratio of 1.22 and a beta of 0.55. The business’s 50-day simple moving average is $53.78. AstraZeneca PLC has a fifty-two week low of $46.48 and a fifty-two week high of $64.94.
A number of research analysts have issued reports on AZN shares. Argus restated a “hold” rating on shares of AstraZeneca in a research report on Monday, April 19th. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research note on Monday, March 8th. SVB Leerink increased their price objective on shares of AstraZeneca from $63.00 to $64.00 and gave the company an “outperform” rating in a research note on Friday, June 4th. Jefferies Financial Group raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Tuesday, March 16th. Finally, Societe Generale restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the stock. AstraZeneca has an average rating of “Buy” and an average target price of $99.33.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
See Also: Range Trading
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.